Teacher Retirement System of Texas Grows Position in bluebird bio Inc (BLUE)

Teacher Retirement System of Texas increased its holdings in bluebird bio Inc (NASDAQ:BLUE) by 317.2% during the fourth quarter, HoldingsChannel reports. The firm owned 15,383 shares of the biotechnology company’s stock after purchasing an additional 11,696 shares during the period. Teacher Retirement System of Texas’ holdings in bluebird bio were worth $2,740,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Schwab Charles Investment Management Inc. raised its holdings in shares of bluebird bio by 51.9% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 266,693 shares of the biotechnology company’s stock worth $36,631,000 after purchasing an additional 91,161 shares in the last quarter. Tocqueville Asset Management L.P. raised its holdings in shares of bluebird bio by 78.0% in the 3rd quarter. Tocqueville Asset Management L.P. now owns 55,690 shares of the biotechnology company’s stock worth $7,649,000 after purchasing an additional 24,400 shares in the last quarter. Great West Life Assurance Co. Can raised its holdings in shares of bluebird bio by 22.7% in the 3rd quarter. Great West Life Assurance Co. Can now owns 5,531 shares of the biotechnology company’s stock worth $778,000 after purchasing an additional 1,022 shares in the last quarter. Janus Henderson Group PLC bought a new stake in shares of bluebird bio in the 2nd quarter worth approximately $5,252,000. Finally, California Public Employees Retirement System raised its holdings in shares of bluebird bio by 1.5% in the 3rd quarter. California Public Employees Retirement System now owns 86,100 shares of the biotechnology company’s stock worth $11,826,000 after purchasing an additional 1,300 shares in the last quarter.

bluebird bio Inc (BLUE) opened at $205.45 on Wednesday. bluebird bio Inc has a 1 year low of $73.95 and a 1 year high of $222.03. The company has a market cap of $10,460.19, a P/E ratio of -29.27 and a beta of 2.07.

A number of equities research analysts have recently issued reports on the stock. Leerink Swann lowered shares of bluebird bio from an “outperform” rating to a “market perform” rating and boosted their price target for the company from $162.00 to $194.00 in a report on Thursday, January 25th. Canaccord Genuity restated a “buy” rating and set a $250.00 price target on shares of bluebird bio in a report on Thursday, February 1st. SunTrust Banks boosted their price target on shares of bluebird bio to $223.00 and gave the company a “buy” rating in a report on Tuesday, December 12th. Wells Fargo & Co restated an “outperform” rating and set a $242.00 price target (up previously from $190.00) on shares of bluebird bio in a report on Tuesday, December 12th. Finally, BidaskClub upgraded shares of bluebird bio from a “buy” rating to a “strong-buy” rating in a report on Friday, January 26th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. bluebird bio currently has an average rating of “Hold” and an average target price of $161.45.

In other bluebird bio news, CEO Nick Leschly sold 5,435 shares of the business’s stock in a transaction that occurred on Friday, January 5th. The shares were sold at an average price of $173.38, for a total value of $942,320.30. Following the completion of the sale, the chief executive officer now directly owns 171,009 shares of the company’s stock, valued at $29,649,540.42. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Mark Vachon sold 7,000 shares of the business’s stock in a transaction that occurred on Monday, December 11th. The stock was sold at an average price of $216.64, for a total transaction of $1,516,480.00. Following the completion of the sale, the director now directly owns 8,000 shares of the company’s stock, valued at $1,733,120. The disclosure for this sale can be found here. Insiders have sold 200,280 shares of company stock worth $37,818,846 over the last ninety days. 3.90% of the stock is currently owned by insiders.

WARNING: “Teacher Retirement System of Texas Grows Position in bluebird bio Inc (BLUE)” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/21/teacher-retirement-system-of-texas-grows-position-in-bluebird-bio-inc-blue.html.

bluebird bio Company Profile

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio Inc (NASDAQ:BLUE).

Institutional Ownership by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply